@article{article, title  = {{EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer}},

 publisher = {{Elsevier BV}},

 url = {{http://dx.doi.org/10.1093/annonc/mdu269 }},

 year = {{2014}},

 month = {{7}},

 author = {{Heymach JV and Lockwood SJ and Herbst RS and Johnson BE and Ryan AJ}},

 doi = {{10.1093/annonc/mdu269}},

 volume = {{25}},

 journal = {{Annals of Oncology}},

 issue = {{10}},

 pages = {{1941-1948}},

 note = {{Accessed on 2024/12/22}}}